Tagged with MS

Puerto Rico Juan Ignacio Diddi, GM of BMS Puerto Rico & Caribbean, has over 20 years of experience in the pharmaceutical industry, having held various roles across Latin America before taking on the role leading BMS Puerto Rico and the Caribbean in 2022. He focuses on ensuring early access to therapies, fostering…

Switzerland Industry stakeholders are raising the alarm about access to innovative medicines in Switzerland. Do delays in market access compared to other countries in Europe not only threaten the health of patients in Switzerland, but the country’s status as a global biopharmaceutical R&D hub?   Major Challenges As outlined elsewhere in…

Switzerland Switzerland is the 22nd biggest country in Europe in terms of population yet plays host to a full 20 percent of the continent’s life science companies, with over 1,000 operational firms. Over 0.5 percent of the entire Swiss population (48,000 out of 8.8 million) work in the life sciences, 67…

Switzerland Intricacy, precision, and quality. These are bywords for Switzerland’s world-renowned watchmaking industry, but which could equally apply to its biopharmaceutical manufacturing footprint. As with top-end models from Rolex, Tag Heuer, or Breitling, made-in-Switzerland pharmaceuticals do not necessarily come cheap, but the country’s network of life science manufacturers seem content that…

Puerto Rico Dr. Eduardo Nicolau shares his journey from being a professor of chemistry to becoming Executive Director of the MSRC in 2021. His leadership focuses on financial stability, creating a biotech incubator, and establishing key partnerships with the industry, including a significant collaboration with the biotechnology company CytoImmune Therapeutics for cancer…

Switzerland Jérôme Garcin, newly appointed General Manager of Bristol-Myers Squibb (BMS) Switzerland, shares his journey to the role and discusses the strategic importance of the Swiss affiliate within the global BMS network. In this interview, he highlights BMS’s focus on innovation across therapeutic areas such as oncology, hematology, cardiology and neurology,…

Switzerland Dimitri Gitas, Managing Director of MSD Switzerland, discusses the strategic importance of Switzerland, not only as a management hub for the company, but as a manufacturing location and clinical research centre where its clinical trials have grown to over 60 per year. Gitas also shares MSD’s key focus areas in…

Mexico The lowest spender on healthcare as a percentage of GDP in mainland Latin America. A complex and fragmented reimbursement system. Clinical trial approval delays stretching across eight months. One could be forgiven for thinking that attempting to bring innovative medicines to Mexico is a thankless task. Yet, as several country…

Mexico Oswaldo Bernal explains how Mexico is BMS’ top-performing market in Latin America (outside of Brazil) and plays a significant role in the company’s global growth strategy. He also discusses how Mexican patients face hurdles in accessing new treatments due to low health investment and lengthy regulatory approval processes, as well…

Europe This year’s European Society of Medical Oncology (ESMO) was the largest ever. Over 33,000 people attended ESMO Congress 2024 at Barcelona’s cavernous Fira Gran Via conference centre, where 5,000 abstracts were presented and 600 expert speakers took to the stage. The healthcare professionals and cancer drug developers in attendance were…

Global Originally seen as occasional service providers for the pharma industry, contract development and manufacturing organisations (CDMOs) have become vital strategic partners. Helping pharma and biotech companies advance their therapies through their outsourced services, CDMOs have demonstrated their ability to respond to the industry’s shifting priorities as well as its pre-…

Mexico This year has seen no less than five GM changes at international pharma companies’ Mexican affiliates. Pfizer, MSD, Roche, Sanofi and Gilead have all taken on new local leadership. In some cases, the appointments represent a first for affiliates that have never had female leaders while in others they coincide…